Safety and glycaemic outcomes of insulin-containing regimens in patients with type 2 diabetes mellitus during Ramadan: a systematic review and meta-analysis
In adults with type 2 diabetes mellitus, insulin-containing regimens during Ramadan were associated with a modest reduction in HbA 1c ; however, the clinical significance of this reduction remains uncertain.
Abstract
Ramadan fasting poses significant challenges for individuals with type 2 diabetes mellitus (T2DM), particularly those treated with insulin. This systematic review and meta-analysis evaluates the impact of insulin-based therapy on glycemic control and hypoglycemia in adults with T2DM during Ramadan.
Following PRISMA guidelines, we searched PubMed, Embase, and the Cochrane Library from inception to January 2025 for studies reporting on pre- and post-Ramadan HbA
1c
and hypoglycemia in insulin-treated patients with T2DM. Both observational and interventional studies were included in this meta-analysis. Pooled analysis of HbA
1c
change was conducted using the random-effects model.
Twenty studies (
n
= 2024 pre-Ramadan,
n
= 1979 post-Ramadan) were included. Insulin regimens varied, including basal, premixed, basal-bolus, and combinations with oral injectable hypoglycemic agents. When analyzed by study design, randomized controlled trials (RCTs) showed a significant reduction in HbA
1c
(mean difference (MD) = -0.38; 95% CI: -0.49 to -0.27,
p
< 0.00001; I² = 35%), while observational studies also demonstrated a smaller but significant reduction (-0.33; 95% CI -0.59 to -0.06,
p
= 0.02; I² = 82%). Sensitivity analyses using fixed-effect models confirmed the robustness of these findings, with persistent statistical significance and reduced heterogeneity. The incidence of hypoglycemia was stable or reduced in most studies, though definitions and reporting methods were inconsistent. A pooled analysis of studies reporting the number of hypoglycemic events (
n
= 5; mixed randomized and observational designs) showed no significant difference before and during Ramadan (SMD − 0.06; 95% CI: −0.25 to 0.13;
p
= 0.52; I² = 0%), and subgroup analysis by study design was not feasible.
In adults with T2DM, insulin-containing regimens during Ramadan were associated with a modest reduction in HbA
1c
; however, the clinical significance of this reduction remains uncertain. The available evidence did not demonstrate an increase in hypoglycaemia, but this finding should be interpreted cautiously given the small number of studies and variability in hypoglycaemia definitions and reporting. Individualized insulin management and structured pre-Ramadan education remain essential to optimize safety during fasting.
Not applicable.
Intensive insulin therapy (IIT) induces clinical remission in newly diagnosed or poorly controlled type 2 diabetes mellitus (T2DM), but is limited by hypoglycemia risk and weight gain. Combining IIT with non-insulin antihyperglycemic agents may mitigate these drawbacks while improving glycemic variability....
Zi-Xuan Shen, Jia-Wei Li, Zi-Yun Zhao et al.· Frontiers in Endocrinology· 0 citations
Background / Aim: In Type 2 diabetes, Multiple Daily Injection (MDI) is effective but associated with hypoglycemia, weight gain, and poor adherence. Despite the growing endorsement of basal insulin plus GLP-1 receptor Agonist (GLP-1RA) as a streamlined therapeutic step-down, a pooled synthesis that encompasses every pu...
Sarah Albishri, Reema Alshaya, Eyas Alharbi et al.· International Journal of Med...· 0 citations
BACKGROUND
The effectiveness of continuous glucose monitoring (CGM) in adults with type 2 diabetes (T2D) not receiving intensive insulin therapy remains incompletely established, particularly regarding glycemic metrics beyond glycated hemoglobin (HbA1c).
METHODS
We conducted a systematic review and meta-analysis of r...
A. A. Al Hayek, Wael M. Alzahrani, Haifa F. Alotaibi et al.· Journal of Diabetes Science...· 0 citations
Once-weekly IcoSema delivers meaningful improvements in weight, blood pressure, and atherogenic lipids, all key modifiable drivers of ASCVD in adults with type 2 diabetes and suggests potential for enhanced ASCVD prevention and improved long-term adherence.
Adir Alper, Adina Fagin, A. Karthikeyan et al.· Cardiovascular Diabetology· 1 citation
Background: The global rise of type 2 diabetes (T2D) presents significant healthcare challenges in diagnosis, prevention, and treatment. This study compares basal insulin and modified-release gliclazide to assess their effectiveness in managing glycemic control and other clinical factors in T2D patients. Methods: This...
This systematic review and meta‐analysis aimed to compare GLP‐1 receptor agonist (GLP‐1RA)‐based prandial insulin de‐intensification with continued basal–bolus insulin therapy (BBI) or multiple daily injections (MDI) in adult outpatients with type 2 diabetes receiving established BBI/MDI at randomisation.
Hong-Xia Yang, Tian-Li Ren, Jin Zhou et al.· Diabetes, obesity and metabo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.